LEPR Deficiency Obesity Clinical Trial
Official title:
A Phase 2, Single-arm, Open-label Study to Assess Efficacy and Safety of LB54640 in Patients With Obesity Due to POMC, PCSK1, or LEPR Deficiency.
The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity
Patients with obesity due to POMC, PCSK1 or LEPR deficiency will be enrolled to receive LB54640 by oral administration for 16 weeks. After 16 weeks of treatment, the participant may enter a long term extension phase and receive treatment for up to 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04966741 -
Setmelanotide in Pediatric Patients With Rare Genetic Diseases of Obesity
|
Phase 3 | |
| Completed |
NCT03621007 -
An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR Genes
|